| Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice X Xiang, D Feng, S Hwang, T Ren, X Wang, E Trojnar, C Matyas, R Mo, ... Journal of hepatology 72 (4), 736-745, 2020 | 142 | 2020 |
| Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223–enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis Y He, RM Rodrigues, X Wang, W Seo, J Ma, S Hwang, Y Fu, E Trojnár, ... The Journal of clinical investigation 131 (3), 2021 | 114 | 2021 |
| Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications C Matyas, G Haskó, L Liaudet, E Trojnar, P Pacher Nature Reviews Cardiology 18 (2), 117-135, 2021 | 76 | 2021 |
| The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a … A Bhattacharjee, S Reuter, E Trojnár, R Kolodziejczyk, H Seeberger, ... Journal of biological chemistry 290 (15), 9500-9510, 2015 | 75 | 2015 |
| PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease JS Lee, P Mukhopadhyay, C Matyas, E Trojnar, J Paloczi, YR Yang, ... Scientific reports 9 (1), 17167, 2019 | 64 | 2019 |
| Interplay of liver–heart inflammatory axis and cannabinoid 2 receptor signaling in an experimental model of hepatic cardiomyopathy C Matyas, K Erdelyi, E Trojnar, S Zhao, ZV Varga, J Paloczi, ... Hepatology 71 (4), 1391-1407, 2020 | 59 | 2020 |
| Shiga Toxin Type 1a (Stx1a) Reduces the Toxicity of the More Potent Stx2a In Vivo and In Vitro CD Petro, E Trojnar, J Sinclair, ZM Liu, M Smith, AD O’Brien, ... Infection and immunity 87 (4), 10.1128/iai. 00787-18, 2019 | 28 | 2019 |
| Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome E Trojnar, K Erdelyi, C Matyas, S Zhao, J Paloczi, P Mukhopadhyay, ... Free Radical Biology and Medicine 152, 540-550, 2020 | 26 | 2020 |
| Analysis of linear antibody epitopes on factor H and CFHR1 using sera of patients with autoimmune atypical hemolytic uremic syndrome E Trojnár, M Józsi, K Uray, D Csuka, Á Szilágyi, D Milosevic, ... Frontiers in Immunology 8, 302, 2017 | 13 | 2017 |
| Autoantibodies against the complement regulator factor H in the serum of patients with neuromyelitis optica spectrum disorder B Uzonyi, Z Szabó, E Trojnár, S Hyvärinen, K Uray, HH Nielsen, A Erdei, ... Frontiers in Immunology 12, 660382, 2021 | 10 | 2021 |
| PCSK9, a promising novel target for age-related cardiovascular dysfunction C Matyas, E Trojnar, S Zhao, M Arif, P Mukhopadhyay, A Kovacs, ... Basic to Translational Science 8 (10), 1334-1353, 2023 | 8 | 2023 |
| A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy GB Karvaly, I Karádi, I Vincze, MN Neely, E Trojnár, Z Prohászka, É Imreh, ... Pharmacology Research & Perspectives 9 (5), e00856, 2021 | 7 | 2021 |
| Elevated systemic pentraxin-3 is associated with complement consumption in the acute phase of thrombotic microangiopathies E Trojnar, M Józsi, Z Szabó, M Réti, P Farkas, K Kelen, GS Reusz, ... Frontiers in Immunology 10, 240, 2019 | 7 | 2019 |
| Data-driven transcriptomics analysis identifies PCSK9 as a novel key regulator in liver aging M Arif, C Matyas, P Mukhopadhyay, B Yokus, E Trojnar, J Paloczi, ... GeroScience 45 (5), 3059-3077, 2023 | 3 | 2023 |
| PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury J Wagner, LM Park, P Mukhopadhyay, C Matyas, E Trojnar, R Damadzic, ... Brain, Behavior, and Immunity 119, 494-506, 2024 | 2 | 2024 |
| Role of complement in the pathogenesis of thrombotic microangiopathies E Trojnár, Á Szilágyi, B Mikes, D Csuka, G Sinkovits, Z Prohászka memo-Magazine of European Medical Oncology 11, 227-234, 2018 | 1 | 2018 |
| PCSK9 INHIBITION AS A NOVEL THERAPEUTIC TARGET FOR ALCOHOLIC LIVER DISEASE J Lee, P Mukhopadhyay, C Matyas, E Trojnar, J Paloczi, YR Yang, ... ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 44, 45-45, 2020 | | 2020 |
| Investigation of the molecular background of alternative pathway dysregulation in thrombotic microangiopathies E Trojnar | | 2020 |
| PCSK9 and the Liver-Brain Axis: A Novel Therapeutic Target for Alcohol Use Disorder J Lee, P Mukhopadhyay, C Matyas, E Trojnar, J Paloczi, D Rosoff, ... NEUROPSYCHOPHARMACOLOGY 44 (SUPPL 1), 530-530, 2019 | | 2019 |
| WHOLE EXOME SEQUENCING IN ATYPICAL HEMOLYTIC UREMIC SYNDROME AND GLOMERULOPATHY D Csuka, N Garam, N Veszeli, E Trojnar, B Mezo, A Szilagyi, Z Prohaszka MOLECULAR IMMUNOLOGY 114, 471-471, 2019 | | 2019 |
